Literature DB >> 8576314

CpG DNA: a pathogenic factor in systemic lupus erythematosus?

A M Krieg1.   

Abstract

Systemic lupus erythematosus (SLE) is a multifactorial disease of unknown etiology. Characteristic features of SLE include (1) polyclonal B cell activation, (2) overexpression of the immune stimulatory cytokine interleukin-6 (IL-6), (3) defective tolerance to self antigens, and (4) production of anti-DNA antibodies (Ab). Bacterial infection has been suspected as a triggering factor for lupus. Bacterial DNA differs from vertebrate DNA in the frequency and methylation of CpG dinucleotides. These CpG motifs in bacterial DNA induce a variety of immune effects, including (1) polyclonal activation of murine and human B cells, (2) IL-6 secretion, and (3) resistance to apoptosis, thereby potentially allowing the survival of autoreactive cells. These results suggest that microbial DNA could therefore be a pathogenic factor in SLE. SLE patients have elevated levels of circulating plasma DNA which is reportedly enriched in hypomethylated CpGs. Genomic DNA is also hypomethylated in SLE. The purpose of this review is to summarize the immune effects of CpG motifs and to present the evidence for their possible involvement in the pathogenesis of SLE.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8576314     DOI: 10.1007/bf01541318

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  72 in total

Review 1.  Interferons and interferon inducers in cancer treatment.

Authors:  S E Krown
Journal:  Semin Oncol       Date:  1986-06       Impact factor: 4.929

2.  Membrane-associated DNA in the cytoplasm of diploid human lymphocytes.

Authors:  R A Lerner; W Meinke; D A Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  1971-06       Impact factor: 11.205

3.  Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis.

Authors:  B Richardson; L Scheinbart; J Strahler; L Gross; S Hanash; M Johnson
Journal:  Arthritis Rheum       Date:  1990-11

4.  DNA binding to human leukocytes. Evidence for a receptor-mediated association, internalization, and degradation of DNA.

Authors:  R M Bennett; G T Gabor; M M Merritt
Journal:  J Clin Invest       Date:  1985-12       Impact factor: 14.808

5.  Nucleosomes and DNA bind to specific cell-surface molecules on murine cells and induce cytokine production.

Authors:  S H Hefeneider; K A Cornell; L E Brown; A C Bakke; S L McCoy; R M Bennett
Journal:  Clin Immunol Immunopathol       Date:  1992-06

6.  Quantitation and characterization of plasma DNA in normals and patients with systemic lupus erythematosus.

Authors:  L Raptis; H A Menard
Journal:  J Clin Invest       Date:  1980-12       Impact factor: 14.808

7.  Stage-specific oligonucleotide uptake in murine bone marrow B-cell precursors.

Authors:  Q Zhao; T Waldschmidt; E Fisher; C J Herrera; A M Krieg
Journal:  Blood       Date:  1994-12-01       Impact factor: 22.113

8.  Increased spontaneous secretion of IL-6 from B cells of patients with B chronic lymphatic leukaemia (B-CLL) and autoimmunity.

Authors:  N Lahat; E Aghai; B Maroun; A Kinarty; M Quitt; P Froom
Journal:  Clin Exp Immunol       Date:  1991-08       Impact factor: 4.330

9.  Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity.

Authors:  E Cornacchia; J Golbus; J Maybaum; J Strahler; S Hanash; B Richardson
Journal:  J Immunol       Date:  1988-04-01       Impact factor: 5.422

10.  Induction of cross-reactive anti-dsDNA antibodies in preautoimmune NZB/NZW mice by immunization with bacterial DNA.

Authors:  G S Gilkeson; A M Pippen; D S Pisetsky
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808

View more
  30 in total

Review 1.  Rescue of B cells from apoptosis by immune stimulatory CpG DNA.

Authors:  A M Krieg; A K Yi
Journal:  Springer Semin Immunopathol       Date:  2000

Review 2.  Activation of the innate immune system by CpG oligodeoxynucleotides: immunoprotective activity and safety.

Authors:  D M Klinman; S Kamstrup; D Verthelyi; I Gursel; K J Ishii; F Takeshita; M Gursel
Journal:  Springer Semin Immunopathol       Date:  2000

3.  RNAs in the sera of Persian Gulf War veterans have segments homologous to chromosome 22q11.2.

Authors:  H B Urnovitz; J J Tuite; J M Higashida; W H Murphy
Journal:  Clin Diagn Lab Immunol       Date:  1999-05

4.  Dysregulation of apoptosis as mechanism supporting the induction of autoimmunity.

Authors:  Hanns-Martin Lorenz; Joachim R Kalden
Journal:  Curr Rheumatol Rep       Date:  2004-08       Impact factor: 4.592

5.  Innate immune responses in lupus-prone Palmerston North mice: differential responses to LPS and bacterial DNA/CpG oligonucleotides.

Authors:  Petar Lenert; Adam Goeken; Barry S Handwerger; Robert F Ashman
Journal:  J Clin Immunol       Date:  2003-05       Impact factor: 8.317

Review 6.  Synthetic oligonucleotides as modulators of inflammation.

Authors:  Dennis Klinman; Hidekazu Shirota; Debra Tross; Takashi Sato; Sven Klaschik
Journal:  J Leukoc Biol       Date:  2008-04-22       Impact factor: 4.962

Review 7.  Antibody responses to DNA in normal immunity and aberrant immunity.

Authors:  D S Pisetsky
Journal:  Clin Diagn Lab Immunol       Date:  1998-01

8.  Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon-alpha (IFN-alpha) production acting on leucocytes resembling immature dendritic cells.

Authors:  H Vallin; S Blomberg; G V Alm; B Cederblad; L Rönnblom
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

9.  Down-regulation of ATP-binding cassette transporter G1 expression by unmethylated CpG oligodeoxynucleotides in RAW 264.7 macrophages.

Authors:  Jeong Min Seo; Ji-Young Lee; Geun Eog Ji; Ji Chang You
Journal:  Exp Mol Med       Date:  2011-09-30       Impact factor: 8.718

10.  TLR-9 activation of marginal zone B cells in lupus mice regulates immunity through increased IL-10 production.

Authors:  Petar Lenert; Rachel Brummel; Elizabeth H Field; Robert F Ashman
Journal:  J Clin Immunol       Date:  2005-01       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.